Cell Signaling Technology, Inc. (CST) is a private, family owned, worldwide leader in the development and commercialization of antibodies, assays and research tools. As a company of scientists for scientists, we have developed XMT® technology, a proprietary method to develop exceptional monoclonal antibodies, PTMScan®, a technology to discover protein post-translational modifications, and PhosphoSitePlus®, an online resource for investigation of post-translational modifications. We are passionate about our role in contributing to the life science industry’s advancing of the human condition through accelerating the discovery and development of innovative therapies for human disease. We are fully committed to developing new research tools to help define the mechanisms underlying cell function and disease, thereby broadly accelerating progress in biomedical research and medicine.
